Clinical efficacy of Lianhua Qingwen integrated with Western medicine on COVID-19 by Meta-analysis / 中草药
Chinese Traditional and Herbal Drugs
;
(24): 3763-3769, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-846305
ABSTRACT
Objective:
To systematically evaluate the efficacy of Lianhua Qingwen (LQC) on COVID-19, and provide evidence for the formulation and optimization of clinical therapy on COVID-19.Methods:
Six databases (PubMed, Cochrane Library, Wanfang, Weipu, CBM and CNKI) were searched up to May 27, 2020. The Cochrane collaborative bias risk tool was used for risk evaluation and quality assessment; Meta-analysis was carried out by Stata 15 software. Begg's test was used for publication bias.Results:
Seven clinical trials were included with 665 COVID-19 patients. Compared with Western medicine alone, integrated Lianhua Qingwen significantly improved the effective rate of clinical symptoms [RR = 1.24, 95% CI (1.12, 1.38), P < 0.05] of COVID-19, increased CT improvement [RR = 1.14, 95% CI (1.02, 1.28), P < 0.05] and reduced the proportion of progressing into sever clinical level [RR = 0.48, 95% CI (0.31, 0.72), P < 0.05]; In addition, integrated Lianhua Qingwen could effectively shorten the duration of fever [SMD = -0.87, 95% CI (-1.22,-0.52), P < 0.05], time of clinical symptoms disappearance [SMD = -1.19, 95% CI (-1.56, -0.82), P < 0.05] and hospital stay [SMD = -0.61, 95% CI (-0.91, -0.30), P < 0.05].Conclusion:
Lianhua Qingwen could be used as adaptive and complementary medicine to improve clinical symptoms and CT for COVID-19.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Revisiones Sistemáticas Evaluadas
Idioma:
Chino
Revista:
Chinese Traditional and Herbal Drugs
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS